Recent News

Posted by Burton on January 19th, 2015 in Headlines Corporate Announcements  ⟩  0 comments

Lee Biosolutions is scheduled to expand into its new 41,000 sq. ft facility at 10850 Metro Ct, Maryland Heights MO in August after adding over $1 million dollars of improvements to the  of the of a state-of-the-art manufacturing facility. CEO & President, Burton Lee states, “ We are excited about our seamless transition to a larger facility which is designed for maximum flexibility for complex manufacturing processes. This expansion will enable LB to meet our ever growing product line as well as ensure improved on time delivery to our customers."  

Lee Biosolutions success has been the ability to develop some of the most successful products in the industry and the ability to provide expertise in purification, development and process chromatography to our clients.

Lee Biosolutions is a privately held corporation headquartered in St. Louis, MO manufacturing high purity finished enzymes and proteins for the diagnostic, academic and scientific industry worldwide. Our innovative preparative and analytical techniques allows us to meet both research and bulk cGMP manufacturing requirements.

Burton Lee

President and CEO

Posted by Burton on July 1st, 2014 in Headlines Corporate Announcements  ⟩  0 comments

ST LOUIS, July 2, 2014 -- Lee Biosolutions Inc, a leading biotech company in the healthcare field serving the Global diagnostic industry is proud to announce that it will expand into a new 40,786 Sq.ft facility in the City of Maryland Heights end of 4th quarter 2014 . The need for a new space is in response to the companies rising growth into new markets and increased demand for its products.

The building was previously home to one of the KV Pharmaceuticals cutting edge facilities that dotted the surrounding business landscape in St. Louis County. The Increased analytical lab space is needed for Lee Bio's increased growth for bioanalytical research and development projects and its ever expanding bulk manufacturing requirements. The added capacity and resources will help the company achieve its projected growth through 2017.

Burton Lee, President and CEO says ,"With the rapid growth we have seen over the last few years, our current facility was not able to keep up with demand. The new building supports our strategic objective to further expand our product lines, increase our capacity on key contract manufacturing products requiring larger cGMP processing clean rooms and to create operational efficiencies to meet our clients requirements."

The company plans on doubling its payroll by 2016 and is currently seeking qualified candidates to fill several positions by first quarter next year. The company has set up a career page to easily fill out and send in your resume.

Lee Biosolutions success in the aquisition of this outstanding new facility was achieved by having a great team which included Dan Dokovic from Intelica CRE, Kelly Shamel from Greensfelder Hemker & Gale, P.C, Jack Mannebach and Stephen Kuhn of Heartland Bank, Steve Grelle from the St. Louis Economic Development Partnership and The City Of Maryland Heights.

Lee Biosolutions is a key manufacturer of high purity enzymes and related proteins that include tumor markers, cardiac markerS, specialty diagnostic proteins for immunological diseases and biomarkers. The company is known internationally for developing some of the most successful formulations for research, diagnostic and therapeutic markets.

You can learn more about the company, its products, services and career opportunities by visiting its website at

Posted by Burton on May 5th, 2014 in Featured Community Partner Profiles  ⟩  0 comments


Lee Biosolutions has expanded our community outreach program to include a wonderful organization called Great Circle. Lee Biosolutions contributed $10,000 in 2013 and volunteered for Great Circle this holiday season that helped the Edgewood Children's Home and Hitchcock School programs. These caring individuals specialize in helping children that are abused , are in foster care and  have varying degrees of Autism and  Asperger's Syndrome.  Washington University works closely them developing innovative learning methods .   You can find dedicated counselors and therapists  going to a  child's home or in the worst case scenarios the child is brought to Edgewood where they can stay for months for special treatment.  This year we sponsored Career Day for the Science Class and had them visit our facility. We are also currently developing an internship program for these students.   

Posted by Burton on August 7th, 2013 in Headlines  ⟩  0 comments
Lee Biosolutions, is a manufacturer and producer of high purity proteins announces a major scientific breakthrough. The St. Louis-based biotechnology firm recently developed a proprietary process to effectively and efficiently purify and stabilize two important gastric cancer protein biomarkers. As a result, they are producing Pepsinogen I and Pepsinogen II, critical components in serum pepsinogen tests that will revolutionize early detection of stomach and gastric cancer.

According to American Association for Cancer Research (AACR), stomach cancer is the second-leading cause of cancer-related deaths worldwide and the top cause in Eastern Asia, which comprises China, Japan, Taiwan and Korea. Studies have shown that if the disease is detected early, patients five-year survival rates increases by 90 percent. Asian and European governments have been advocating mass screenings for decades, but traditional upper endoscopy procedures are painful, invasive and expensive. Lee Biosolutions proteins Pepsinogen I and Pepsinogen II production capabilities enables international diagnostics companies to quickly manufacture serum pepsinogen tests, which are affordable and easy to administer. Lee has scaled up production to meet global market demand.

"Gastric cancer screening involves H Pylori infection detection, measurement of serum pepsinogen I and II levels and possibly endoscopic examination.  ," said Burton Lee, president of Lee Biosolutions. "The challenge to-date for diagnostic companies  has been producing  tests efficiently and affordably. Recently, Lee Biosolutions research and development team cracked the code for purifying and stabilizing two very important gastric and stomach cancer protein biomarkers, Pepsinogen I and Pepsinogen II, primary components in serum pepsinogen tests. We now have the expertise, processes and manufacturing capacity to produce enough of these biomarkers to make a significant impact."

Serum pepsinogen tests for gastric cancer enable healthcare providers to identify high risk patients for further monitoring. Not only do the tests increase survival rates by 90 percent but they also decrease the cost of mass screening programs. Lee currently has clients in Eastern Asia and Europe that plan to produce, distribute and administer the tests.

About Lee Biosolutions, Inc.
Lee Biosolutions is an international producer of high purity human, animal and recombinant proteins, biological fluids, biochemicals, antibodies and immunoreagents. Headquartered in St. Louis and founded in 1975, the biotechnology firm serves academic and scientific researchers as well as IVD manufacturers worldwide. Lee Biosolutions produces and processes the raw biomaterials used in drug discovery and development, laboratory equipment calibration, clinical diagnosis and product testing. These include human neutrophil elastase, human myeloperoxidase isoform c, alpha fetoprotein, beta 2 microglobulin, and amylase. The company is ISO 9001:2008 certified, FDA registered and meets USDA guidelines. To learn more about Lee Biosolutions visit .
Posted by Burton on June 9th, 2013 in Headlines  ⟩  0 comments

Lee Biosolutions Inc, a U.S. manufacturer, producer and supplier of high purity proteins and antigens announces the isolation and increased production of Serum Tumor Markers for the management of testicular germ cell tumors. The St. Louis-based healthcare- biotechnology firm has developed a unique proprietary process to effectively and efficiently purify beta Human Chorionic Gonadotropin, Alpha fetoprotein and Lactate dehydrogenase. As a result, Lee is now is a preferred producer for researchers and diagnostic companies to supply these critical components that are used in early detection of testicular cancer.

According to the American Cancer Society, there will be almost 9000 new cases of testicular cancer diagnosed in the United States this year. Although the rate of testicular cancer is rising for unknown reasons worldwide the death rate is low because of early detection and advances in the treatment of testicular cancer. Testicular cancer can develop in one or both testicles with over 90 percent of cancers in the testicle develop in special cells known as germ cells. Germ cells Scientists have found few risk factors that make a man more likely to develop testicular cancer.

Lee’s testicular germ cell tumor marker production capabilities enables in vitro diagnostics companies to manufacture diagnostic tests , which are affordable and easy to administer. Lee has scaled up production to meet global market demand. Beta Human Chorionic Gonadotropin (Beta HCG), alpha fetoprotein (AFP ) and Lactate Dehydrogenase (LDH) produced by Lee Biosolutions are used in the management of testicular germ cell tumors.

“Lee Biosolutions is on the forefront of Testicular Cancer research by supplying highly purified markers such as beta HCG, alpha fetoprotein and lactate dehydrogenase. Most testicular cancers are found by men themselves. If a lump is detected the doctor would recommend blood tests to determine levels of tumor markers to determine the proper diagnosis. Testicular cancer is survivable if treated early enough by the removal of the testicle. Its when you ignore the signs and you find yourself with Stage III cancer that has spread to the lungs, liver, bones and brain that survival rates diminish,” said Burton Lee, President of Lee Biosolutions.

Lee BioSolutions is an international producer and supplier of high purity finished proteins. Headquartered in St. Louis and founded in 2002, the healthcare biotechnology firm serves academic and scientific researchers as well as IVD manufacturers worldwide. Lee BioSolutions produces and processes raw biomaterials used in drug discovery and development, diagnostic controls and calibrators, clinical diagnosis and product testing. The company is ISO 9001:2008 certified, FDA registered and meets USDA guidelines. For more information go to Lee Biosolutions website at